151 related articles for article (PubMed ID: 17135996)
1. Steady-state clinical pharmacokinetics of bupropion extended-release in youths.
Daviss WB; Perel JM; Birmaher B; Rudolph GR; Melhem I; Axelson DA; Brent DA
J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1503-9. PubMed ID: 17135996
[TBL] [Abstract][Full Text] [Related]
2. Steady-state pharmacokinetics of bupropion SR in juvenile patients.
Daviss WB; Perel JM; Rudolph GR; Axelson DA; Gilchrist R; Nuss S; Birmaher B; Brent DA
J Am Acad Child Adolesc Psychiatry; 2005 Apr; 44(4):349-57. PubMed ID: 15782082
[TBL] [Abstract][Full Text] [Related]
3. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
Jefferson JW; Pradko JF; Muir KT
Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
[TBL] [Abstract][Full Text] [Related]
4. Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study.
Daviss WB; Perel JM; Brent DA; Axelson DA; Rudolph GR; Gilchrist R; Nuss S; Birmaher B
Ther Drug Monit; 2006 Apr; 28(2):190-8. PubMed ID: 16628130
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers.
Zhang F; Li Y; Hu J; Zhong J; Li H
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):339-352. PubMed ID: 30520001
[TBL] [Abstract][Full Text] [Related]
6. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender.
Stewart JJ; Berkel HJ; Parish RC; Simar MR; Syed A; Bocchini JA; Wilson JT; Manno JE
J Clin Pharmacol; 2001 Jul; 41(7):770-8. PubMed ID: 11452710
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults.
Kharasch ED; Neiner A; Kraus K; Blood J; Stevens A; Miller JP; Lenze EJ
Clin Pharmacol Ther; 2020 Nov; 108(5):1036-1048. PubMed ID: 32386065
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion.
Laib AK; Brünen S; Pfeifer P; Vincent P; Hiemke C
Ther Drug Monit; 2014 Aug; 36(4):473-9. PubMed ID: 24452068
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion.
Kustra R; Corrigan B; Dunn J; Duncan B; Hsyu PH
J Clin Pharmacol; 1999 Nov; 39(11):1184-8. PubMed ID: 10579150
[TBL] [Abstract][Full Text] [Related]
10. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
Stang P; Suppapanaya N; Hogue SL; Park D; Rigney U
Am J Ther; 2007; 14(3):241-6. PubMed ID: 17515697
[TBL] [Abstract][Full Text] [Related]
11. Bupropion sustained release: a therapeutic overview.
Davidson JR; Connor KM
J Clin Psychiatry; 1998; 59 Suppl 4():25-31. PubMed ID: 9554318
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
Kharasch ED; Lenze EJ
Drug Metab Dispos; 2024 Apr; 52(5):455-466. PubMed ID: 38467432
[TBL] [Abstract][Full Text] [Related]
13. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects.
Kim H; Bae SK; Park SJ; Shim EJ; Kim HS; Shon JH; Liu KH; Shin JG
Br J Clin Pharmacol; 2010 Jul; 70(1):126-31. PubMed ID: 20642555
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.
Fokina VM; Xu M; Rytting E; Abdel-Rahman SZ; West H; Oncken C; Clark SM; Ahmed MS; Hankins GD; Nanovskaya TN
Drug Metab Dispos; 2016 Nov; 44(11):1832-1838. PubMed ID: 27528039
[TBL] [Abstract][Full Text] [Related]
15. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.
Wilens TE; Haight BR; Horrigan JP; Hudziak JJ; Rosenthal NE; Connor DF; Hampton KD; Richard NE; Modell JG
Biol Psychiatry; 2005 Apr; 57(7):793-801. PubMed ID: 15820237
[TBL] [Abstract][Full Text] [Related]
16. Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.
Masters AR; Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z
J Pharmacol Exp Ther; 2016 Aug; 358(2):230-8. PubMed ID: 27255113
[TBL] [Abstract][Full Text] [Related]
17. Dose-related reduction in bupropion plasma concentrations by ritonavir.
Park J; Vousden M; Brittain C; McConn DJ; Iavarone L; Ascher J; Sutherland SM; Muir KT
J Clin Pharmacol; 2010 Oct; 50(10):1180-7. PubMed ID: 20484617
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers.
Hsyu PH; Singh A; Giargiari TD; Dunn JA; Ascher JA; Johnston JA
J Clin Pharmacol; 1997 Aug; 37(8):737-43. PubMed ID: 9378846
[TBL] [Abstract][Full Text] [Related]
19. Better patient persistence with once-daily bupropion compared with twice-daily bupropion.
Stang P; Young S; Hogue S
Am J Ther; 2007; 14(1):20-4. PubMed ID: 17303971
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial.
Kharasch ED; Neiner A; Kraus K; Blood J; Stevens A; Schweiger J; Miller JP; Lenze EJ
Clin Pharmacol Ther; 2019 May; 105(5):1164-1174. PubMed ID: 30460996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
